All news from Transfusion Medicine

Celltrion And Teva Announces Rituximab Biosimilar

Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted unanimously 16-0 to recommend approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan® (rituximab) for the treatment of adult patients in three proposed indications.